Chemoradiotherapy for advanced cervical cancer—new data from the European Society for Medical Oncology (ESMO) Congress 2023 Radiochemotherapie bei fortgeschrittenem Zervixkarzinom – neue Daten vom European Society for Medical Oncology(ESMO)-Kongress 2023
Gaasch A, Corradini S, Czogalla B, Trillsch F (2024)
Publication Type: Journal article
Publication year: 2024
Journal
Book Volume: 19
Pages Range: 364-370
Journal Issue: 9
DOI: 10.1007/s11654-024-00594-0
Abstract
Combined chemoradiotherapy has been the standard nonsurgical treatment for locally advanced cervical cancer since the 1990s. Guidelines also recommend chemoradiotherapy in the definitive or adjuvant setting for patients with inoperable tumors or risk factors. At the 2023 congress of the European Society for Medical Oncology (ESMO), new studies were presented that expand the current treatment standards and will lead to long-term changes in the treatment landscape.
Involved external institutions
Germany (DE)How to cite
APA:
Gaasch, A., Corradini, S., Czogalla, B., & Trillsch, F. (2024). Chemoradiotherapy for advanced cervical cancer—new data from the European Society for Medical Oncology (ESMO) Congress 2023 Radiochemotherapie bei fortgeschrittenem Zervixkarzinom – neue Daten vom European Society for Medical Oncology(ESMO)-Kongress 2023. Best Practice Onkologie, 19(9), 364-370. https://doi.org/10.1007/s11654-024-00594-0
MLA:
Gaasch, Aurélie, et al. "Chemoradiotherapy for advanced cervical cancer—new data from the European Society for Medical Oncology (ESMO) Congress 2023 Radiochemotherapie bei fortgeschrittenem Zervixkarzinom – neue Daten vom European Society for Medical Oncology(ESMO)-Kongress 2023." Best Practice Onkologie 19.9 (2024): 364-370.
BibTeX: Download